Edition:
United States

IMV Announces Early Positive Results From Phase 2 Clinical Trial Of Lead Candidate DPX-Survivac In Combination With Merck’S Keytruda In Patients With DLBCL


Tuesday, 18 Sep 2018 07:05am EDT 

Sept 18 (Reuters) - Imv Inc ::IMV INC. ANNOUNCES EARLY POSITIVE RESULTS FROM PHASE 2 CLINICAL TRIAL OF LEAD CANDIDATE DPX-SURVIVAC IN COMBINATION WITH MERCK’S KEYTRUDA® IN PATIENTS WITH DLBCL.IMV INC - DATA SHOWED TWO OF FIRST FOUR EVALUABLE PARTICIPANTS SHOWED TUMOR REGRESSIONS AT FIRST ON-TREATMENT CT SCAN.IMV INC - IN TRIAL, COMBINATION THERAPY APPEARS TO DEMONSTRATE AN ACCEPTABLE SAFETY PROFILE, WITH NO SERIOUS ADVERSE EVENTS REPORTED TO DATE.IMV INC - FIRST ENROLLED PARTICIPANT DEMONSTRATED A TUMOR REGRESSION OF 48% AT FIRST ON-TREATMENT SCAN.IMV INC - SECOND PARTICIPANT DEMONSTRATED A PARTIAL RESPONSE (PR) VIA A TUMOR REGRESSION OF 66% AT FIRST ON-TREATMENT SCAN.IMV INC - PRELIMINARY DATA FROM THIRD PARTICIPANT IN TRIAL OF DPX-SURVIVAC IN COMBINATION WITH KEYTRUDA DEMONSTRATED STABLE DISEASE.IMV INC - FOURTH PARTICIPANT HAD EARLY DISEASE PROGRESSION LESS THAN TWO MONTHS FOLLOWING TREATMENT INITIATION AND WAS DISCONTINUED FROM STUDY.